Researchers from “IP-cure-B” & “TherVacB” continue the dialogue to advance elimination of chronic hepatitis B

Researchers from the two EC-funded projects  ‘IP-cure-B – Take care of your health’ and ‘TherVacB – A therapeutic vaccine to cure Hepatitis B’ continue their collaboration to jointly tackle some of the major challenges in the therapy of viral hepatitis.

Building on a first exploratory session in summer 2023, a wider team of researchers are meeting on 5^th June 2024 for a 2^nd round of strategic discussions. The workshop is hosted by both consortia at the Congress of the European Association for the Study of the Liver (EASL) 2024 in Milano, Italy, and held at the Milano Convention Centre “Allianz MiCo” in the South Wing Level 2 meeting room “Amber 6”. 

In 2020, work on chronic hepatitis B by the research and clinical communities in the two projects had kicked-off in parallel. Funded by the European Commission under the same topic, both research teams have adopted stratified host-directed approaches to raise awareness and improve prevention, treatment and functional cure of hepatitis B.  

At EASL 2024, a larger group of IP-cure-B and TherVacB experts in virology, immunology and clinical hepatitis will engage in focused discussions on the different aspects of viral hepatitis B infection (HBV) and the HBV-mediated chronic disease that they are investigating to reduce the global health burden: 

• the therapeutic approaches,
• the clinical trials,
• virologic monitoring, immune profiling and biomarker identification &
• the TherVacB Patient Registry.